BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 32556947)

  • 1. Prostate-specific antigen testing after the US Preventive Services Task Force recommendation: a population-based analysis of electronic health data.
    Frendl DM; Epstein MM; Fouayzi H; Krajenta R; Rybicki BA; Sokoloff MH
    Cancer Causes Control; 2020 Sep; 31(9):861-867. PubMed ID: 32556947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
    Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
    Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations.
    Jemal A; Fedewa SA; Ma J; Siegel R; Lin CC; Brawley O; Ward EM
    JAMA; 2015 Nov; 314(19):2054-61. PubMed ID: 26575061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decrease in Prostate Cancer Testing Following the US Preventive Services Task Force (USPSTF) Recommendations.
    Li J; Berkowitz Z; Hall IJ
    J Am Board Fam Med; 2015; 28(4):491-3. PubMed ID: 26152440
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in Prostate-Specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening.
    Leapman MS; Wang R; Park H; Yu JB; Sprenkle PC; Cooperberg MR; Gross CP; Ma X
    JAMA Oncol; 2022 Jan; 8(1):41-47. PubMed ID: 34762100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of the USPSTF Grade D Recommendation Against Prostate-Specific Antigen Screening With Prostate Cancer-Specific Mortality.
    Burgess L; Aldrighetti CM; Ghosh A; Niemierko A; Chino F; Huynh MJ; Efstathiou JA; Kamran SC
    JAMA Netw Open; 2022 May; 5(5):e2211869. PubMed ID: 35576008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
    Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
    BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testing and referral patterns in the years surrounding the US Preventive Services Task Force recommendation against prostate-specific antigen screening.
    Hutchinson R; Akhtar A; Haridas J; Bhat D; Roehrborn C; Lotan Y
    Cancer; 2016 Dec; 122(24):3785-3793. PubMed ID: 27658175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of the United States Preventive Services Task Force (USPTSTF) recommendations against prostate-specific antigen (PSA) testing on PSA testing in Australia.
    Zargar H; van den Bergh R; Moon D; Lawrentschuk N; Costello A; Murphy D
    BJU Int; 2017 Jan; 119(1):110-115. PubMed ID: 27454454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
    Drazer MW; Huo D; Eggener SE
    J Clin Oncol; 2015 Aug; 33(22):2416-23. PubMed ID: 26056181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation.
    Cohn JA; Wang CE; Lakeman JC; Silverstein JC; Brendler CB; Novakovic KR; McGuire MS; Helfand BT
    Urol Oncol; 2014 Jan; 32(1):41.e23-30. PubMed ID: 23911680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen testing: men's responses to 2012 recommendation against screening.
    Squiers LB; Bann CM; Dolina SE; Tzeng J; McCormack L; Kamerow D
    Am J Prev Med; 2013 Aug; 45(2):182-9. PubMed ID: 23867025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abrogation of survival disparity between Black and White individuals after the USPSTF's 2012 prostate-specific antigen-based prostate cancer screening recommendation.
    Kim IE; Jang TL; Kim S; Modi PK; Singer EA; Elsamra SE; Kim IY
    Cancer; 2020 Dec; 126(23):5114-5123. PubMed ID: 32888321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. State-by-state Variation in Prostate-specific Antigen Screening Trends Following the 2011 United States Preventive Services Task Force Panel Update.
    Vetterlein MW; Dalela D; Sammon JD; Karabon P; Sood A; Jindal T; Meyer CP; Löppenberg B; Sun M; Trinh QD; Menon M; Abdollah F
    Urology; 2018 Feb; 112():56-65. PubMed ID: 29056579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012.
    Butler SS; Muralidhar V; Zhao SG; Sanford NN; Franco I; Fullerton ZH; Chavez J; D'Amico AV; Feng FY; Rebbeck TR; Nguyen PL; Mahal BA
    Cancer; 2020 Feb; 126(4):717-724. PubMed ID: 31794057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of the prostate-specific antigen (PSA) test in the United States for men age ≥65, 1999-2015: Implications for practice interventions.
    Shahangian S; Fan L; Sharma KP; Siegel DA
    Cancer Rep (Hoboken); 2021 Aug; 4(4):e1352. PubMed ID: 33932150
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening.
    Jemal A; Culp MB; Ma J; Islami F; Fedewa SA
    J Natl Cancer Inst; 2021 Jan; 113(1):64-71. PubMed ID: 32432713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changing Incidence of Metastatic Prostate Cancer by Race and Age, 1988-2015.
    Dall'Era MA; deVere-White R; Rodriguez D; Cress R
    Eur Urol Focus; 2019 Nov; 5(6):1014-1021. PubMed ID: 29735368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
    JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Similar perspectives on prostate cancer screening value and new guidelines across patient demographic and PSA level subgroups: A qualitative study.
    Partin MR; Lillie SE; White KM; Wilt TJ; Chrouser KL; Taylor BC; Burgess DJ
    Health Expect; 2017 Aug; 20(4):779-787. PubMed ID: 27807905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.